Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061

Gastric Cancer. 2021 Nov;24(6):1341. doi: 10.1007/s10120-021-01248-8.
No abstract available

Publication types

  • Published Erratum